Why QuidelOrtho’s latest update matters for shareholders

QuidelOrtho (QDEL) has drawn fresh attention after reporting fourth quarter and full year 2025 results, issuing 2026 revenue guidance, and outlining an upcoming CFO transition with an extended handover period.

Despite the earnings update, 2026 revenue guidance and leadership changes around the CFO and board, the recent 30 day share price return of 13.67% decline and 1 year total shareholder return of 27.89% loss show longer term pressure. At the same time, the 90 day share price return of 29.85% hints at some recovering momentum from a low base.

If this kind of earnings driven volatility has your attention, it could be a good moment to see what else is setting up in diagnostics and treatment using our healthcare focused 25 healthcare AI stocks.

With the shares down sharply over 1 and 3 years, trading at a discount to analyst targets and some intrinsic value estimates despite ongoing losses, you have to ask: is this a reset entry point, or is the market already pricing in future growth?

Most Popular Narrative: 24.9% Undervalued

QuidelOrtho’s most followed narrative pegs fair value at $38.33 per share versus a last close of $28.80, putting a sizeable gap between the story and the current price.

Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.

Curious what earnings path and margin rebuild sit behind that fair value, and how a future profit multiple ties to a modest revenue growth outlook? The full narrative lays out the assumptions driving that $38 handle and the tension between ongoing losses today and the valuation the market could one day assign.

Result: Fair Value of $38.33 (UNDERVALUED)

However, you still have to weigh the ongoing drag from COVID testing and product discontinuations, along with China pricing pressures, which could limit the payoff from that 24.9% undervaluation story.

Build Your Own QuidelOrtho Narrative

If you are not convinced by this view or simply want to test your own assumptions against the same data, you can build a tailored QuidelOrtho story in just a few minutes using Do it your way.

A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you like pressure tested opportunities, do not stop at one stock. Line up a few candidates from different angles so you are ready when the market moves.

• Target potential mispricing by scanning our list of 51 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their underlying strength.
• Collect income focused names by reviewing the 13 dividend fortresses that combine higher yields with characteristics many investors look for when building a payout focused portfolio.
• Add resilience to your watchlist by checking companies in the 85 resilient stocks with low risk scores that score well on our internal risk framework before headlines catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.